Chinook Therapeutics Inc.
Chinook Therapeutics is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases. We plan to initiate a phase 3 trial for our lead program, atrasentan, in IgA nephropathy and a phase 2 trial in primary glomerular diseases in early 2021. We seek to build our pipeline by leveraging insights in single cell RNA sequencing of patient kidney samples, human-derived organoids and new translational models to discover and develop therapeutics with mechanisms of action targeted against key kidney disease pathways.